Mikhail V. Blagosklonny graduated with an MD and PhD from First Pavlov State Medical
University of St. Petersburg, RUS. Dr. Misha V. Blagosklonny subsequently Immigrated to the USA, where he received the prestigious Fogarty Fellowship from the National Institutes of Health.
Within the period of his fellowship in Leonard Neckers’ lab at the National
Cancer Institute (NCI), he was a co-author of 18 publications on
Diverse biomedical themes, like targeting
HSP90, p53, Bcl2, Erb2, and Raf-1. He also was the last writer on a clinical phase I/II
Trial article.
After authoring seven papers within the period of a brief yet fruitful
Senior research fellowship in the El-Deiry Cancer Research Lab at the University of Pennsylvania,
Dr. Blagosklonny returned to NCI to work with Tito Fojo. Together, they
Published 26 papers. In addition, Dr. Misha Blagosklonny published anumber of experimental research articles and theoretical articles as sole
Author. Those sole-author publications
Encompassed two important topics.
The first of these focused on selectively killing cancer
Cells with deregulated cell cycle or drug resistance via
Confirming their resistance. The outcomes and underlying
Concept were so revolutionary that they were improperly cited by
Other scientists as “reversal of resistance, ” even though the paper was
Titled, “Exploiting of drug resistance instead of its reversal. ” One major
Supporter of this concept was the world-famous scientist Arthur Pardee, with whom Dr.
Blagosklonny co-authored a joint publication in 2001.
The second topic throughout Dr. Blagosklonny’s sole-author works
Is a research method to create knowledge by
Bringing several facts together from seemingly unrelated fields.
This results in new concepts containing testable forecasts, which in
Turn can be “tested” by analyzing the literature further. Likewise, the
Concept was co-authored by Arthur Pardee in a 2002 article in Nature. The
First success of the new research methodology was the description of the feedback
Regulation of p53, as confirmed by the discovery of mdm2/p53 loop; and the
Explanation why mutant p53 is always overexpressed, published in 1997. The most
Important outcome discovered by Dr.
Blagosklonny’s research methodology is the hyperfunction (or quasi-programmed)
Theory of aging and the revelation of rapamycin as an exceptionally well-tolerated
Anti-aging drug, published in 2006. As mentioned in Scientific American,
Michael Hall, who discovered mTOR in 1991, gives Dr. Blagosklonny credit for “connecting dots that others can’t even see. ”
In 2002, Dr. Blagosklonny became associate professor of medicine at New York Medical College.
He agreed to assume responsibilities as a senior scientist at Ordway
Research Institute in Albany, New York, in 2005, prior to accepting another
Position at Roswell Park Cancer Institute as professor of oncology in 2009.
Since coming to Roswell Park Comprehensive Cancer Center in 2009, Dr. Blagosklonny
Has studied the prevention of cancer (an age-related disease) via
Inhibiting organism aging — in other words, “preventing cancer
By remainng young. ” His laboratory closely collaborated with
Andrei Gudkov’s and finalized research on the suppression of
Cellular senescence, namely suppression of cellular conversion from healthy quiescence to
Permanent senescence. This led to the discovery of extra anti-aging
Medicines besides rapamycin. The cell culture studies were
Accompanied by studies in mice, including several models such as
Normal and aging mice, p53-deficient mice, and mice on a high-fat diet.
Dr. Mikhail Blagosklonny has also published extensively on the prevention of cellular
Senescence by rapamycin and other mTOR inhibitors, life
Extension and cancer prevention in mice, and combinations of anti-
Aging drugs to be used in humans. A
Rapamycin-based combination of seven clinically available drugs has
Been named the “Koschei Formula” and is now used for the treatment of aging in patients
At the Alan Green Clinic in Little Neck, New York.
Misha V. Blagosklonny graduated with an MD and PhD from First Pavlov State Medical
University of St. Petersburg, RUS. Dr. Mikhail V. Blagosklonny subsequently
Moved to the USA, where he received the prestigious Fogarty Fellowship from the National Institutes of Health.
During his fellowship in Leonard Neckers’ laboratory at the National
Cancer Institute (NCI), he was a co-author of 18 publications on various biomedical topics, including targeting
HSP90, p53, Bcl2, Erb2, and Raf-1. He also was the last writer on a clinical phase I/II
Trial paper.
After authoring seven papers within the period of a brief yet productive
Senior research fellowship in the El-Deiry Cancer Research Lab at the University of Pennsylvania,
Dr. Blagosklonny returned to NCI to cooperate with Tito Fojo. Together, they
Published 26 papers. In addition, Dr. Misha Blagosklonny published dozens of experimental research articles and theoretical papers as sole writer. Those sole-author articles
Encompassed two important topics.
The first of those focused on selectively killing cancer
Cells with deregulated cell cycle or drug resistance by
Verifying their resistance. The outcomes and underlying
Concept were so revolutionary that they were inadequately cited by
Other scientists as “reversal of resistance, ” even though the work was
Titled, “Exploiting of drug resistance instead of its reversal. ” One major
Supporter of this concept was the world-famous scientist Arthur Pardee, with whom Dr.Blagosklonny co-authored a joint paper in 2001.
The second theme throughout Dr. Blagosklonny’s sole-author publications
Is a research method to develop knowledge by
Uniting several facts together from seemingly unrelated areas.
This results in new concepts containing testable predictions, which in
Turn can be “tested” by analyzing the literature further. Likewise, the
Notion was co-authored by Arthur Pardee in a 2002 article in Nature. The
First success of the new research methodology was the description of the feedback
Regulation of p53, as confirmed by the discovery of mdm2/p53 loop; and the
Explanation why mutant p53 is always overexpressed, published in 1997. The most
Crucial result revealed by Dr.Blagosklonny’s research methods is the hyperfunction (or quasi-programmed)
Theory of aging and the revelation of rapamycin as an exclusively well-tolerated
Anti-aging medication, published in 2006. As mentioned in Scientific American,
Michael Hall, who discovered mTOR in 1991, gives Dr. Blagosklonny credit for
“connecting dots that others can’t even see. ”
In 2002, Dr. Blagosklonny became associate professor of medicine at New York Medical College.
He decided to accept responsibilities as a senior scientist at Ordway
Research Institute in Albany, New York, in 2005, before receiving another
Position at Roswell Park Cancer Institute as professor of oncology in 2009.
Since joining Roswell Park Comprehensive Cancer Center in 2009, Dr. Blagosklonny
Has studied the prevention of cancer (an age-related disease) via
Inhibiting body aging — in other words, “preventing cancer
By staying young. ” His laboratory closely worked together with
Andrei Gudkov’s and finalized research on the suppression of
Cellular senescence, namely suppression of cellular conversion from healthy quiescence to
Permanent senescence. This resulted in the discovery of extra anti-aging
Drugs besides rapamycin. The cell culture studies were
Accompanied by studies in mice, including several models like
Standard and aging mice, p53-deficient mice, and mice on a high-fat diet.
Dr. Mikhail Blagosklonny has also published extensively on the stoppage of cellular
Senescence by rapamycin as well as other mTOR inhibitors, life
Prolongation and cancer stoppage in mice, and combinations of anti-
Aging drugs to be used in humans. A
Rapamycin-based combination of seven clinically available drugs has
Been named the “Koschei Formula” and is now utilized for the treatment of aging in patients
At the Alan Green Clinic in Little Neck, New York.
Качественные услуги врача-стоматолога. Лечение кариеса зубов с постановкой пломб из современных фотополимерных материалов. Косметическая реставрация зубов. Съемное (бюгельные протезы с замковыми креплениями) и несъемное протезирование (металлокерамические , безметалловые и мостовидные протезы). Профессиональная гигиена и отбеливание зубов, детский прием.
